MEDFARMOS LABORATORIJOS - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 96,560 | 143,245 | 100,538 | 143,204 | 132,475 | 247,227 | 285,236 | 292,829 |
| Profit before tax | -8,138 | 10,689 | -10,910 | 3,229 | 27,652 | 58,964 | 83,650 | 38,463 |
| Net profit | -8,138 | 10,333 | -10,910 | 3,229 | 24,825 | 50,978 | 71,026 | 26,200 |
| Equity | 264,036 | 273,739 | 262,828 | 260,145 | 291,647 | 342,625 | 413,647 | 477,169 |
| Liabilities | 194,617 | 57,356 | 67,478 | 73,357 | 53,463 | 58,025 | 66,119 | 72,443 |
| Non-current assets | 4,458 | 19,454 | 19,335 | 19,981 | 22,829 | 83,212 | 63,340 | 70,403 |
| Current assets | 454,195 | 311,641 | 310,971 | 313,521 | 322,281 | 317,438 | 416,426 | 479,209 |
| Total assets | 458,653 | 331,095 | 330,306 | 333,502 | 345,110 | 400,650 | 479,766 | 549,612 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 22,158 | 33,278 | 40,518 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -16.0% | +48.3% | -29.8% | +42.4% | -7.5% | +86.6% | +15.4% | +2.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -1.8% | 3.1% | -3.3% | 1.0% | 7.2% | 12.7% | 14.8% | 4.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -3.1% | 3.8% | -4.2% | 1.2% | 8.5% | 14.9% | 17.2% | 5.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -8.4% | 7.2% | -10.9% | 2.3% | 18.7% | 20.6% | 24.9% | 8.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -8.4% | 7.5% | -10.9% | 2.3% | 20.9% | 23.9% | 29.3% | 13.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.7 | 0.2 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 32,187 | 71,623 | 50,269 | 71,602 | 66,238 | 123,614 | 142,618 | 146,415 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
MEDFARMOS LABORATORIJOS - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-02-18 | 2026-02-22 | 782.82 |
| 2026-01-16 | 2026-01-19 | 859.18 |
| 2025-11-18 | 2025-11-27 | 767.53 |
| 2025-05-16 | 2025-05-18 | 752.46 |
| 2024-01-16 | 2024-01-21 | 42.67 |
| 2023-06-16 | 2023-06-19 | 14.46 |
| 2022-02-17 | 2022-02-20 | 3.83 |
| 2021-11-16 | 2021-11-17 | 7.28 |
MEDFARMOS LABORATORIJOS - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-06-01 | 2026-06-01 | 1009.67 |
| 2026-05-31 | 2026-05-31 | 994.16 |
| 2026-05-29 | 2026-05-30 | 773.79 |
| 2025-11-02 | 2025-11-09 | 0.15 |
| 2025-10-30 | 2025-11-01 | 0.27 |
| 2025-09-28 | 2025-10-24 | 0.27 |
| 2025-09-19 | 2025-09-25 | 0.27 |
| 2025-05-17 | 2025-05-19 | 219.54 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
MEDFARMOS, UAB, code 124484379, is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €292.8K, up 2.7% year on year and 18.4% over two years. Net profit fell to €26.2K from €71.0K in 2024 and €51.0K in 2023, while the profit margin narrowed to 8.9% from 24.9% and 20.6% in the prior two years. The revenue trend remained positive, but profitability weakened materially in the latest year. The balance sheet strengthened further in 2025: total assets reached €549.6K, equity was €477.2K, and liabilities were €72.4K. The equity ratio stood at 86.8%, with a debt-to-equity ratio of 0.15. Return on equity was 5.5% and return on assets 4.8%, while asset turnover was 0.53x. Revenue per employee was €146.4K and profit per employee €13.1K, indicating a modestly productive operating profile.